CereVasc
Developing solutions for the treatment of patients with communicating hydrocephalus.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $70.0m | Series B | |
| Total Funding | 000k | ||
Related Content
CereVasc, Inc. is a medical device company focused on developing innovative endovascular solutions for the treatment of communicating hydrocephalus, a condition characterized by an abnormal accumulation of cerebrospinal fluid in the brain. The company's flagship product, the eShunt System, is currently under development and aims to offer a less invasive alternative to traditional surgical methods. This system has the potential to deliver therapy across the blood-brain barrier, reducing the complications and uncertainties associated with current treatments like intrathecal injections or ommaya reservoir implantation.
CereVasc operates primarily in the medical device market, targeting healthcare providers and institutions that treat neurological conditions. The company generates revenue through the development and eventual commercialization of its patented technologies. By aggressively pursuing patent protection both in the United States and internationally, CereVasc aims to secure a competitive edge in the market.
The business model involves continuous innovation and development of its core technologies, followed by strategic partnerships and licensing agreements to bring these solutions to market.
Keywords: endovascular, hydrocephalus, eShunt System, blood-brain barrier, intrathecal injection, ommaya reservoir, patent protection, medical device, neurological treatment, healthcare.